Cost-effectiveness and Pricing of Antibacterial Drugs
نویسندگان
چکیده
Growing resistance to antibacterial agents has increased the need for the development of new drugs to treat bacterial infections. Given increasing pressure on limited health budgets, it is important to study the cost-effectiveness of these drugs, as well as their safety and efficacy, to find out whether or not they provide value for money and should be reimbursed. In this article, we systematically reviewed 38 cost-effectiveness analyses of new antibacterial agents. Most studies showed the new antibacterial drugs were cost-effective compared to older generation drugs. Drug pricing is a complicated process, involving different stakeholders, and has a large influence on cost-effectiveness. Value-based pricing is a method to determine the price of a drug at which it can be cost-effective. It is currently unclear what the influence of value-based pricing will be on the prices of new antibacterial agents, but an important factor will be the definition of 'value', which as well as the impact of the drug on patient health might also include other factors such as wider social impact and the health impact of disease.
منابع مشابه
Economic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...
متن کاملValue Assessment and Pricing Frameworks for Rare Disease Treatments: New Approaches From The Literature.
• It has been 15 years since the introduction of orphan medicinal product (OMP) legislation in the EU. Until 2014, one hundred and twelve orphan drugs had been approved in Europe1. • Orphan drugs represent a particular challenge to payers due to the large unmet patient need, paucity of disease information and high per-patient costs2. As of yet, there is no consensus on the most appropriate fram...
متن کاملPricing and reimbursement of orphan drugs: the need for more transparency
Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, legislators, health care professionals, industry leaders, academics and patients. This study aims to conduct a literature review to provide insight into the drivers of orphan drug pricing and reimbursement. Although orphan drug pricing follows the same economic logic as drug pricing in general, the monopo...
متن کاملThe antibacterial paradox: essential drugs, effectiveness, and cost.
The concept proposed by WHO of an essential drugs list that should comprise drugs corresponding to the health needs of the majority of the people has been embraced by countries, which have adapted it to their needs. In this study, the essential antibacterial drug lists of 16 countries chosen from the six WHO regions are reviewed. Most of these countries include 73% of WHO-recommended essential ...
متن کاملA new mathematical model for the closed-loop supply chains considering pricing for product, a fleet of heterogeneous vehicles, and inventory costs
Mathematical models have been used in many areas of supply chain management. In this paper, we present a mixed-integer non-linear programing (MINLP) model to solve a multi-period, closed-loop supply chains (CLSCs) with two echelons consist of producers and customers. In order to satisfy the demands, the producers are be able to order for materials in the beginning of each period for one or more...
متن کامل